Product Description
Canfosfamide is a modified glutathione analogue and nitrogen mustard prodrug, with potential antineoplastic activity. Canfosfamide is selectively activated by glutathione S-transferase P1-1 into an alkylating metabolite that forms covalent linkages with nucleophilic centers in tumor cell DNA, which may induce a cellular stress response and cytotoxicity, and decrease tumor cell proliferation. Glutathione S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Canfosfamide)
Mechanisms of Action: Glutathione Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MabVax Holdings
Company Location: SAN DIEGO CA 92121
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Ovarian Cancer|Peritoneal Cancer|Non-Small-Cell Lung Cancer|Fallopian Tube Cancer
Phase 2: Breast Cancer|Ovarian Cancer|Non-Small-Cell Lung Cancer|Multiple Myeloma|Mantle-Cell Lymphoma|Diffuse Large B-Cell Lymphoma|Peritoneal Cancer|Fallopian Tube Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TLK286.2030 | P2 |
Completed |
Mantle-Cell Lymphoma|Multiple Myeloma|Diffuse Large B-Cell Lymphoma |
2012-09-01 |
|
| TLK286.2023 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2009-05-01 |
|
| ASSIST-5 | P3 |
Terminated |
Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer |
2008-12-01 |
|
| ASSIST-3 | P3 |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
2008-07-01 |